Shared from parkinsonsnewstoday.com.
Early treatment with the investigational small molecule golexanolone improved motor and cognitive function and eased signs of fatigue, anxiety, and depression in a rat model of Parkinson’s disease.
The Umecrine Cognition treatment also reduced neuroinflammation and improved dopamine levels, a study found. Golexanolone “could be considered for clinical evaluation in patients,” the researchers said.
“The mechanisms and effects reported here suggest that golexanolone treatment at early stages of Parkinson’s disease may delay disease progression and the need for L-DOPA treatment,” the researchers wrote. L-DOPA, or levodopa, is a mainstay of Parkinson’s treatment that alleviates motor symptoms by increasing dopamine levels.